COVID-19
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Don’t Get Caught In Long-COVID OTC Painkiller ‘Hamster Wheel,’ Warn German Neurologists
A significant proportion of COVID-19 headache sufferers go on to develop “new daily persistent headaches” syndrome. German neurologists warn that these people are at danger of medication overuse headaches, as well as kidney damage, as a result of taking OTC analgesics on a daily basis.
Along With Sales Across Regions And Categories, Perrigo’s Labor Shortage Concerns Grow
“The only thing that keeps me up at night right now is labor shortages,” says CEO Murray Kessler. He also notes growing trend of consumers responding to inflation by moving from national brands to lower-priced private label/store brand OTC drugs.
Prestige Consumer Opens Its FY2023 With Revenue Thirst Quenched By Hydralyte International Sales
Hydralyte line has 90% share in Australia’s hydration market and accounted for a large share of firm’s overall sales growth in its latest quarter as 28.9% international sales growth to $34.5m offset flat North American results at $242.4m.
CPHI Podcast Special: The Supplements Market – From Slump to Surge
In this podcast special, HBW Insight senior editor David Ridley is interviewed by CPHI's Rebecca Lumley about the latest trends in the European dietary supplements space. They discuss which products surged in popularity during the pandemic, the rise of self-care and the current regulatory environment in Europe.
Inflation And COVID Putting Pressure On Europe’s Paracetamol Supply Chain
Inflation, new COVID-19 waves and delayed cold and flu outbreaks are causing disruption to Europe's paracetamol supply chain, according to an investigation by HBW Insight. Industry is not currently concerned, but regulators, for example in France, are introducing measures to prevent this issue spreading from children's to adult forms of the drug, as well as to ibuprofen-based alternatives.
US FDA Explains How It Is Embracing Remote Assessments Post-Pandemic
Agency provides additional details on plans for various remote methods of assessing Rx and OTC drug manufacturing facilities that became popular when investigators were prevented by COVID-19 travel restrictions from visiting sites in person.
J&J Consumer Health Q2 Results No Help For Avoiding Lowering Full-Year Guidance Again
J&J reported lower consumer health sales during its latest quarter; consumer health businesses name and branding to be announced in the next few months.
USANA’s Preliminary Earnings Alert Could Signal Trend In Q2 Results Across Consumer Health
Pandemic-related market lockdowns, shipping backlogs and other disruptions in mainland China and other countries USANA referenced in announcement also could affect results for its direct-selling competitors as well as other firms in health, wellness, personal care and beauty industries.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.